Dane Leone
Stock Analyst at Raymond James
(1.18)
# 3,781
Out of 5,120 analysts
69
Total ratings
33.96%
Success rate
-6.55%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $8.15 | +133.13% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.59 | +580.74% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $10.78 | +317.44% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $97.16 | -69.12% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $755.02 | +25.82% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.16 | +501.85% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $78.24 | -41.21% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $34.23 | +101.58% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $6.52 | +22.70% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $9.15 | +53.01% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $12.11 | +378.94% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $16.77 | +317.41% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.87 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $65.16 | -3.31% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $55.89 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.87 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $65.93 | -1.41% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $344.68 | -26.02% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.00 | +700.00% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $230.75 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $8.15
Upside: +133.13%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.59
Upside: +580.74%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $10.78
Upside: +317.44%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $97.16
Upside: -69.12%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $755.02
Upside: +25.82%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.16
Upside: +501.85%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $78.24
Upside: -41.21%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $34.23
Upside: +101.58%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $6.52
Upside: +22.70%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $9.15
Upside: +53.01%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $12.11
Upside: +378.94%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $16.77
Upside: +317.41%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.87
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $65.16
Upside: -3.31%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $55.89
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.87
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $65.93
Upside: -1.41%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $344.68
Upside: -26.02%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.00
Upside: +700.00%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $230.75
Upside: -